[総説]
1. 景山 茂.医師主導臨床試験の目的と信頼性確保のあり方.医薬ジャーナル 2015; 51(1): 51-5.
2. 景山 茂.医師から見たRMPとその意義.医薬ジャーナル 2013; 49(11): 91(2589)-94(2592).
3. 植田真一郎,景山茂.臨床試験,観察研究におけるデータストレージシステムの活用.薬剤疫学 2013; 18(1): 31-4.
[原著論文]
1. Odawara M (Tokyo Medical Univ), Kawamori R (Juntendo Univ Grad Sch Med), Tajima N, Iwamoto Y (Asahi Life Foundation), Kageyama S, Yodo Y1, Ueki F1 (1: Sumitomo Dainippon Pharma), Hotta N (Chubu Rosai Hosp). Long-term treatment study of global standard dose metformin in Japanese patients with type 2 diabetes mellitus. Diabetol Int 2017. ; 8: 286-95. DOI: 10.1007/s13340-017-0309-z.
2. Kawamori R, Kaku K, Hanafusa T, Ioriya K, Kageyama S, Hotta N. Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin. J Diabetes Investig 2016; 7: 253-259.
3. Kadokura T, Akiyama N, Kashiwagi, Utsuno A, Kazuta K, Yoshida S, Nagase I, Smulders R (Astellas Pharma Global Development Europe, Leiden, The Netherlands ), Kageyama S. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2014; 106(1):50-6.
4. Ooba N, Sato T , Wakana A, Orii T, Kitamura M, Kokan A, Kurata H , Shimodozono Y , Matsui K, Yoshida H, Yamaguchi T, Kageyama S, Kubota K. A prospective stratified case-cohort study on statins and multiple adverse events in Japan. PLoS One 2014; 9(5): e96919.
5. Kawamori R, Kaku K, Hanafusa T, Oikawa T, Kageyama S, Hotta N. Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2014; 5(1): 72-9.
6. Kurihara C, Kusuoka H, Ono S, Kakee N, Saito K, Takehara K, Tsujide K, Nabeoka Y, Sakuhiro T, Aoki H, Morishita N, Suzuki C, Kachi S, Kondo E, Komori Y, Isobe T, Kageyama S, Watanabe H. High rate of awarding compensation for claims of injuries related to clinical trials by pharmaceutical companies in Japan: a questionnaire survey. PLoS One 2014; 9(1): e84998.
7. Yokoyama K, Nakashima A, Urashima M, Suga H, Mimura T, Kimura Y, Kanazawa Y, YokotaT, Sakamoto M, Ishizawa S, Nishimura R, Kurata H, Tanno Y, Tojo K, Kageyama S, Ohkido I, Utsunomiya K, Hosoya T. Interactions between serum vitamin D levels and vitamin D receptor gene FokI polymorphisms for renal function in patients with type 2 diabetes. PLoS One 2012; 7(12) : e51171.
8. Kawamori R, Kaku K, Hanafusa T, Kashiwabara D, Kageyama S, Hotta N. Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus. J Diabet Invest 2012; 3: 302-8.
9. Kadokura T, Saito M, Utsuno A, Kazuta K, Yoshida S, Kawasaki S, Nagase I, Kageyama S. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int 2011: 2: 172-182.
10. Kageyama S, Ueda S, Mochizuki K, Miyakawa M, Sugawara M, Nakayama M, Ohashi Y, Saito I and Saruta T, for the OCEAN Study Group. Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial?rationale, design and results of a pilot study in Japan. Hypertension Research 2012; 35: 221-7.
11. Saito I, Suzuki H, Kageyama S, Saruta T. Treatment of hypertension in patients 85 years of age or older: a J-BRAVE substudy. Clin Exp Hypertens 2011; 33: 275-80.
|